Karuna’s Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade) (NASDAQ:KRTX)


Schizophrenia

wildpixel

Introduction

Karuna Therapeutics (NASDAQ:KRTX) develops innovative treatments for psychiatric and neurological disorders. Their investigational drug, KarXT, targets schizophrenia and Alzheimer’s-related psychosis with a unique mechanism, differing from dopaminergic or serotonergic pathways, offering a potential new treatment option.

In my



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *